Skip to main content
Premium Trial:

Request an Annual Quote

Tranzyme, Quark Biotech Pen Licensing, R&D Collaboration

NEW YORK, May 15 - Tranzyme and Quark Biotech have inked a multi-year research and licensing collaboration, Tranzyme said today.

 

Privately held Tranzyme will give Quark non-exclusive worldwide rights to its gene-expression and drug-discovery technologies TranzVector and TranzAssay in exchange for undisclosed annual research funding and milestone payments, the firms said.

 

In addition, Tranzyme, whose technology focuses on neurosensory diseases, will receive an equity investment from Quark and pocket undisclosed royalties from any products that happen to be developed.

 

Click here for more information.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.